13.09.2010 • NewsPurac

Purac to Build New Plant for Biomedical Resorbable Polymers in the U.S.

Purac announces the investment in a new manufacturing facility for its biomedical polymers. The plant is meant to support the growing resorbable polymers business of Purac biomaterials.

Purac currently operates a plant for biomedical polymers in The Netherlands. This second facility will be built in the U.S. The investment for this new plant will be €15 million. The construction of the facility will start in 2011 and is expected to be completed before the end of the year.

Arno van de Ven, Purac vice president chemicals & pharma comments: "This represents an important step in the biomedical polymer business and shows Purac's continued commitment to this market. It provides us with the capability to support the growth of our existing and new business partners."

Besides an increase in the production capacity, the new facility will bring Purac biomaterials more flexibility and a more balanced presence in its global markets.

Menno Lammers, director of Purac biomaterials comments: "As an experienced supplier to pharmaceutical and medical device companies, we understand the importance of guaranteed supply continuity. Over the last years, the importance of risk management has increased and with this facility we will be in the unique position to provide our customers with dual sourcing".

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.